Skip to content

Efficacy of acupoint autoblood therapy in the treatment of oral lichen planus: a randomized controlled trial protocol

Efficacy of acupoint autoblood therapy in the treatment of oral lichen planus: a randomized controlled trial protocol

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089526
Enrollment
Unknown
Registered
2024-09-10
Start date
2024-02-19
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichen planus

Interventions

Observation group:BL 15 and BL 20 were selected and treated once a week for a total of 8 times. The skin of the elbow was thoroughly cleaned and disinfected. About 6ml of blood was drawn from the vei
Control group:The lesion was treated locally with medicine(glucocorticoid)

Sponsors

The Affiliated Hospital of Nantong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: A. Meet the diagnostic criteria for oral lichen planus; B. Age 18-60 years old; C. Patients without major organic diseases, infectious diseases, blood system diseases, mental diseases, immune system diseases; D. Those who have not participated in other related clinical trials within the past 1 month; E. Willing to undergo 8 weeks of treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: A. Patients who have been treated with corticosteroids or any drug that may cause A lichen-like reaction within the last 1 month; B. Patients who have received local (oral) treatment within the last 2 weeks; C. Pregnant or lactating women; D. Have major heart, brain, liver, kidney and other organic diseases, infectious diseases, blood system diseases, need treatment; E. Patients with various mental diseases, delirium, and inability to cooperate; F. Poor compliance, unable to adhere to treatment; G. histopathological signs of dysplasia.

Design outcomes

Primary

MeasureTime frame
REU score;VAS pain grade;IgA;IgM;IgG;The ratio of CD4 to CD8;The ratio of IFN-? to IL-4;

Countries

China

Contacts

Public ContactMinghui Xia

The Affiliated Hospital of Nantong University

417798466@qq.com+86 138 6194 3235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026